HEXO Corp. (HEXO)
(Delayed Data from AMEX)
$7.73 USD
+0.27 (3.62%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.73 USD
+0.27 (3.62%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -900% and 15.51%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 2.33% and 1.75%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 44.44% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
HEXO (HEXO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of 13.64% and 33.97%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 34.09% and 0.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will HEXO (HEXO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
HEXO (HEXO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of -33.33% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Tops Q4 Earnings Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
HEXO (HEXO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -250% and 19.23%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
HEXO (HEXO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
HEXO (HEXO) closed at $0.16 in the latest trading session, marking a -0.25% move from the prior day.
Will HEXO (HEXO) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
HEXO (HEXO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health (CLOV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.
Here's Why HEXO (HEXO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
HEXO (HEXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
PetIQ (PETQ) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of -200% and 15.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 750% and 4.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 47.06% and 14.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About HEXO Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to HEXO stock based on the movements in the options market lately.
HEXO (HEXO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of 10% and 12.36%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: HEXO (HEXO) Q1 Earnings Expected to Decline
by Zacks Equity Research
HEXO (HEXO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for HEXO Corp (HEXO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to HEXO Corp (HEXO) stock based on the movements in the options market lately.
5 Top Inverse/Leveraged ETFs of Last Week
by Sanghamitra Saha
Big three U.S. indexes including the S&P 500, the Dow Jones, the Nasdaq Composite and the Russell 2000 made last week a winning one for investors.
HEXO (HEXO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -66.67% and 20.00%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?